Blockbuster Early Cancer Detection Technology with Multi-Billion-Dollar, Peer-Proven Potential

Colorectal cancer is the third most common cancer in the world[1], and the 2nd leading cause of cancer death in the USA[2].

Did you already know that it’s highly preventable?

Early detection of colorectal cancer provides survival rates beyond 90%.[3]

The United States Preventive Services Task Force (USPSTF) published in May 2021 new guidelines recommending colorectal cancer screening start at age 45 which translates to a market potential of over 52 million tests per year.

Dominating this space has been ONE success story that sticks out, a biotech company that’s been serving this vastly underpenetrated colorectal screening opportunity since 2014, and growing into a 11-figure valuation along the way.

That story was Exact Sciences Sciences Corporation (NASDAQ:EXAS), and its flagship screening product ColoGuard, which helped grow the company to its current Market Cap of US$16.5-Billion.[4]

Chances are, you missed that opportunity. But don’t worry, we’ve got you covered…

What truly matters is how YOU can take part in this story all over again, this time from the beginning.

We’re about to tell you about an incredibly unique opportunity to participate in the fight against colorectal cancer, that’s already approved for sale in Europe and is beginning the process of gaining FDA approval for sale in North America.

 The company has just completed its IPO, and with an improved more affordable version of the testing technology that made Exact Sciences POP!